MedTrace Logo

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

NCT06679153 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2025-01-27

No results posted yet for this study

Summary

This is a multicenter, double-masked, randomized, active-controlled, parallel-comparison study conducted at sites in the China in subjects with Noninfectious Anterior Uveitis

Conditions

  • Anterior Uveitis

Interventions

DRUG

VVN461 Ophthalmic Solution 1.0%

VVN461 Ophthalmic Solution, 1.0%, for up to 28 days

DRUG

VVN461 Ophthalmic Solution 0.5%

VVN461 Ophthalmic Solution, 0.5%, for up to 28 days

DRUG

Prednisolone acetate

Prednisolone acetate, 1%, for up to 28 days

Sponsors & Collaborators

  • VivaVision Biotech, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-27
Primary Completion
2024-12-29
Completion
2024-12-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06679153 on ClinicalTrials.gov